These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 30295043

  • 1. [Modern treatment of metastatic hormone-sensitive prostate cancer].
    Küronya Z, Bíró K, Géczi L, Maráz A.
    Orv Hetil; 2018 Oct; 159(41):1664-1671. PubMed ID: 30295043
    [Abstract] [Full Text] [Related]

  • 2. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

  • 3. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y, Matsubara N, Takizawa I, Nishiyama T, Tabata K, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H.
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [Abstract] [Full Text] [Related]

  • 4. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S.
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [Abstract] [Full Text] [Related]

  • 5. [Castration resistant prostate cancer 2015].
    Merseburger AS, Böker A, Kuczyk MA, von Klot CA.
    Aktuelle Urol; 2015 Jan; 46(1):59-65. PubMed ID: 25658232
    [Abstract] [Full Text] [Related]

  • 6. [Combination therapy for metastatic hormone-sensitive prostate cancer: What? When? For whom?].
    Thomas C, Ohlmann CH.
    Urologe A; 2020 Jun; 59(6):665-672. PubMed ID: 32274544
    [Abstract] [Full Text] [Related]

  • 7. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K.
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [Abstract] [Full Text] [Related]

  • 8. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST, Posadas EM, Bruce J, Lim EA, Petrylak DP, Peng W, Kheoh T, Maul S, Smit JW, Gonzalez MD, De Porre P, Tran N, Nanus DM.
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [Abstract] [Full Text] [Related]

  • 9. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ, Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [Abstract] [Full Text] [Related]

  • 10. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [Abstract] [Full Text] [Related]

  • 11. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [Abstract] [Full Text] [Related]

  • 12. Sequences and combinations of multifaceted therapy in advanced prostate cancer.
    Vaishampayan UN.
    Curr Opin Oncol; 2015 May; 27(3):201-8. PubMed ID: 25811344
    [Abstract] [Full Text] [Related]

  • 13. Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
    Thomas C, Brandt MP, Baldauf S, Tsaur I, Frees S, Borgmann H, Jäger W, Bartsch G, Schneider M, Dotzauer R, Neisius A, Haferkamp A.
    Int Urol Nephrol; 2018 Oct; 50(10):1821-1827. PubMed ID: 30120678
    [Abstract] [Full Text] [Related]

  • 14. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators.
    Lancet; 2010 Oct 02; 376(9747):1147-54. PubMed ID: 20888992
    [Abstract] [Full Text] [Related]

  • 15. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.
    Eur Urol; 2014 Feb 02; 65(2):289-99. PubMed ID: 23957948
    [Abstract] [Full Text] [Related]

  • 16. [Changes in the treatment of metastatic prostate cancer-new data and open questions].
    Albers P, Bögemann M, Machtens S, Merseburger AS, Schostak M, Steuber T, Wülfing C, De Santis M.
    Urologe A; 2020 Mar 02; 59(3):307-317. PubMed ID: 31781782
    [Abstract] [Full Text] [Related]

  • 17. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
    Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, Climent MÁ, Olmos D, Carles J, Lázaro M.
    Clin Transl Oncol; 2018 Jan 02; 20(1):57-68. PubMed ID: 29134562
    [Abstract] [Full Text] [Related]

  • 18. De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?
    Iacovelli R, Ciccarese C, Mosillo C, Tortora G.
    Clin Genitourin Cancer; 2018 Dec 02; 16(6):482-484. PubMed ID: 30139716
    [Abstract] [Full Text] [Related]

  • 19. Sequencing Treatment for Castration-Resistant Prostate Cancer.
    Handy CE, Antonarakis ES.
    Curr Treat Options Oncol; 2016 Dec 02; 17(12):64. PubMed ID: 27822685
    [Abstract] [Full Text] [Related]

  • 20. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B, Pandor A, Stevenson M, Hamilton J, Chambers D, Clowes M, Graham J, Kumar MS.
    Pharmacoeconomics; 2017 Apr 02; 35(4):415-424. PubMed ID: 27770303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.